Acceleron Pharma Inc.(Nasdaq: XLRN) today announced that results from the MEDALIST and BELIEVE Phase 3 trials of luspatercept in patients with low-to-intermediate risk myelodysplastic syndromes (MDS) and transfusion-dependent beta-thalassemia, respectively, will be presented at the 60th American Society of Hematology(ASH) Annual Meeting & Exposition in San Diego, California, on December 1-4, 2018.
Luspatercept is being developed as part of a global collaboration between Acceleron and Celgene.
The results from the MEDALIST trial will be presented on Sunday, December 2nd during the Plenary Scientific Session, which honors the top six research papers submitted for presentation at the meeting. The ASH Program Committee selected the MEDALIST abstract for inclusion in the Plenary Session from more than 6,500 abstracts submitted this year. The BELIEVE results will be communicated in an oral presentation on Saturday, December 1st.
‘There is no better forum in which to present results than at ASH, the world’s largest hematology meeting. The acceptance of our abstracts for presentation in plenary and oral sessions validates our belief that luspatercept could become a truly transformative therapy for patients with MDS and beta-thalassemia,’ said Habib Dable, President and Chief Executive Officer of Acceleron. ‘We also have multiple ongoing trials in other MDS and beta-thalassemia populations as well as in myelofibrosis-reflecting our confidence in the potential for luspatercept to become a platform medicine for the management of a range of chronic anemias.’
‘We’re thrilled by the prospect of altering the treatment landscapes of MDS and beta-thalassemia with the first novel anemia agent in more than two decades,’ said Robert K. Zeldin, M.D., Chief Medical Officer of Acceleron. ‘The positive results in pivotal trials for two distinct diseases speak to the promise of luspatercept’s unique mechanism of action as an erythroid maturation agent and the potential for its broader applicability to anemias with high unmet medical need. We continue to work diligently with our global collaboration partner, Celgene, to submit global regulatory applications beginning in the first half of 2019.’
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.